The Most Exciting Developments in Retina (Macula Society)

Chairpersons: M. Zarbin USA, P. Dugel USA

 

S. Wolf SWITZERLAND
Analysis of the intestinal microbiome in nvAMD

R. MacLaren UK 
Gene Therapy in Chronic Diseases: Ready or Not?

S. Sivaprasad UK
MacTel: New Insights into Physiology

TBC
C3 Inhibition for Geographic Atrophy in AMD

U. Schmidt-Erfurth AUSTRIA
Why the location of fluid matters in nvAMD

F. Bandello ITALY
Microangiopathy versus neuroretinal damage as the first pathogenic mechanism of diabetic retinopathy

A. Loewenstein ISRAEL
RVO Studies: Results of recent comparative studies

F. Holz GERMANY
Brolucizumab: The next generation anti-VEGFA

P. Dugel USA
The angiopoietin pathway: Impactful or impossible?

M. Zarbin USA
Real life outcomes versus clinical trials: A dangerous gap?

 

Discussion

End of session

Back

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved